NPS Pharmaceuticals receives orphan drug designation for Natpara in Europe NPS Pharmaceuticals announced that the European Commission has granted orphan drug designation to Natpara for the treatment of hypoparathyroidism. Orphan drug designation in the European Union is given to products that are designed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or chronically debilitating. The company was also granted orphan drug status by the U.S. Food and Drug Administration in 2007. The company submitted its U.S. Biologic License Application to FDA in October 2013.
NPS Pharmaceuticals jumps 12%, halted after report of potential Shire bid Shire (SHPG) has NPS Pharmaceuticals (NPSP) on the top of its list of potential takeover targets, but is also said to be considering other targets, according to Bloomberg.